Newsbenzinga
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…